| RS2512983397 |
CACNA1A
|
Health Risk |
Pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2512987953 |
MUC16
|
Health Risk |
Likely pathogenic |
Ovarian cancer, Ovarian cancer |
| RS2513013293 |
NFIX
|
Health Risk |
Likely pathogenic |
Marshall-Smith syndrome, Marshall-Smith syndrome |
| RS2513031029 |
CACNA1A
|
Health Risk |
Pathogenic/Likely pathogenic |
Global developmental delay, Episodic ataxia type 2 |
| RS2513031100 |
CACNA1A
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy, 42 |
| RS2513031267 |
CACNA1A
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy, 42 |
| RS2513031829 |
NFIX
|
Health Risk |
Likely pathogenic |
— |
| RS2513034053 |
DOCK6
|
Health Risk |
Pathogenic |
— |
| RS2513039217 |
DOCK6
|
Health Risk |
Pathogenic/Likely pathogenic |
Adams-Oliver syndrome 2, DOCK6-related disorder |
| RS2513041499 |
CACNA1A
|
Health Risk |
Pathogenic |
Episodic ataxia type 2, Spinocerebellar ataxia type 6 |
| RS2513041740 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513043216 |
ADGRL1
|
Health Risk |
Likely pathogenic |
Developmental delay, behavioral abnormalities |
| RS2513049085 |
CACNA1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513049302 |
CACNA1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Developmental and epileptic encephalopathy, 42 |
| RS2513049322 |
CACNA1A
|
Health Risk |
Pathogenic |
— |
| RS2513055080 |
CACNA1A
|
Health Risk |
Likely pathogenic |
Episodic ataxia type 2, Episodic ataxia type 2 |
| RS2513056055 |
CACNA1A
|
Health Risk |
Pathogenic |
— |
| RS2513061120 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513068920 |
TRMT1
|
Health Risk |
Pathogenic |
Intellectual developmental disorder, autosomal recessive 68 |
| RS2513071407 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513071430 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513071545 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513071572 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513075471 |
UNC13A
|
Health Risk |
Likely pathogenic |
Amyotrophic lateral sclerosis type 1, Amyotrophic lateral sclerosis type 1 |
| RS2513086957 |
TRMT1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2513091106 |
RTTN
|
Health Risk |
Likely pathogenic |
— |
| RS2513093007 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513093326 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513093391 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513094170 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513094283 |
CC2D1A
|
Health Risk |
Pathogenic/Likely pathogenic |
Intellectual disability, autosomal recessive 3 |
| RS2513099410 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513105444 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513105453 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513108777 |
TRMT1
|
Health Risk |
Pathogenic |
Intellectual developmental disorder, autosomal recessive 68 |
| RS2513116527 |
PIGN
|
Health Risk |
Pathogenic |
Multiple congenital anomalies-hypotonia-seizures syndrome 1, Multiple congenital anomalies-hypotonia-seizures syndrome 1 |
| RS2513118015 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513119050 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513124551 |
MUC16
|
Health Risk |
Likely pathogenic |
Ovarian cancer, Ovarian cancer |
| RS2513131323 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513133401 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513137623 |
CC2D1A
|
Health Risk |
Pathogenic |
— |
| RS2513147217 |
CC2D1A
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal recessive 3 |
| RS2513150660 |
CC2D1A
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal recessive 3 |
| RS2513151126 |
CC2D1A
|
Health Risk |
Likely pathogenic |
— |
| RS2513151702 |
CACNA1A
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2513151718 |
CACNA1A
|
Health Risk |
Pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2513151774 |
CACNA1A
|
Health Risk |
Likely pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2513151820 |
CACNA1A
|
Health Risk |
Pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2513152460 |
CACNA1A
|
Health Risk |
Likely pathogenic |
Migraine, familial hemiplegic |
| RS2513154138 |
PIGN
|
Health Risk |
Pathogenic |
Multiple congenital anomalies-hypotonia-seizures syndrome 1, Multiple congenital anomalies-hypotonia-seizures syndrome 1 |
| RS2513156379 |
DOCK6
|
Health Risk |
Pathogenic |
— |
| RS2513161109 |
DOCK6
|
Health Risk |
Pathogenic |
— |
| RS2513175466 |
CACNA1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Developmental and epileptic encephalopathy, 42 |
| RS2513175615 |
CACNA1A
|
Health Risk |
Pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2513188826 |
MAST3
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy 108, Developmental and epileptic encephalopathy 108 |
| RS2513193892 |
MAST3
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy 108, Inborn genetic diseases |
| RS2513200325 |
CACNA1A
|
Health Risk |
Pathogenic/Likely pathogenic |
Episodic ataxia type 2, Developmental and epileptic encephalopathy |
| RS2513201032 |
GTPBP3
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2513204411 |
GTPBP3
|
Health Risk |
Pathogenic |
— |
| RS2513207214 |
GTPBP3
|
Health Risk |
Pathogenic |
— |
| RS2513207346 |
GTPBP3
|
Health Risk |
Likely pathogenic |
Combined oxidative phosphorylation defect type 23, Combined oxidative phosphorylation defect type 23 |
| RS2513214903 |
DOCK6
|
Health Risk |
Pathogenic |
— |
| RS2513228819 |
PLVAP
|
Health Risk |
Likely pathogenic |
Diarrhea 10, protein-losing enteropathy type |
| RS2513229473 |
PLVAP
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2513229533 |
PLVAP
|
Health Risk |
Pathogenic |
— |
| RS2513247583 |
CPAMD8
|
Health Risk |
Likely pathogenic |
Abnormal anterior eye segment morphology, Abnormal anterior eye segment morphology |
| RS2513280986 |
C19orf12
|
Health Risk |
Pathogenic |
Neurodegeneration with brain iron accumulation, C19orf12-related disorder |
| RS2513281713 |
C19orf12
|
Health Risk |
Likely pathogenic |
— |
| RS2513299932 |
C19orf12
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurodegeneration with brain iron accumulation 4, Hereditary spastic paraplegia 43 |
| RS2513300586 |
C19orf12
|
Health Risk |
Likely pathogenic |
Hereditary spastic paraplegia 43, Hereditary spastic paraplegia 43 |
| RS2513305937 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513311644 |
KMT2B
|
Health Risk |
Pathogenic |
Dystonia 28, childhood-onset |
| RS2513315712 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513316153 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513317148 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513318484 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513318630 |
KMT2B
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2513320717 |
LGI4
|
Health Risk |
Likely pathogenic |
Arthrogryposis multiplex congenita 1, neurogenic |
| RS2513320923 |
KMT2B
|
Health Risk |
Likely pathogenic |
— |
| RS2513322968 |
KMT2B
|
Health Risk |
Pathogenic |
— |
| RS2513323502 |
KMT2B
|
Health Risk |
Pathogenic |
Intellectual developmental disorder, autosomal dominant 68 |
| RS2513328286 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513328365 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513328406 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513328486 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513329489 |
CEBPA
|
Health Risk |
Conflicting classifications of pathogenicity |
Acute myeloid leukemia, Inborn genetic diseases |
| RS2513330090 |
LGI4
|
Health Risk |
Likely pathogenic |
Arthrogryposis multiplex congenita 1, neurogenic |
| RS2513330269 |
KMT2B
|
Health Risk |
Likely pathogenic |
Rare genetic intellectual disability, Rare genetic intellectual disability |
| RS2513330332 |
KMT2B
|
Health Risk |
Pathogenic |
Dystonia 28, childhood-onset |
| RS2513331483 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332000 |
CEBPA
|
Health Risk |
Likely pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332280 |
CEBPA
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332781 |
CEBPA
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332790 |
CEBPA
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332810 |
CEBPA
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513332961 |
CEBPA
|
Health Risk |
Pathogenic |
Acute myeloid leukemia, Acute myeloid leukemia |
| RS2513333325 |
KMT2B
|
Health Risk |
Likely pathogenic |
Dystonia 28, childhood-onset |
| RS2513333606 |
DNM2
|
Health Risk |
Likely pathogenic |
Autosomal dominant centronuclear myopathy, Autosomal dominant centronuclear myopathy |
| RS2513336258 |
KMT2B
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |